This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Stable isotope labeling involves the use of non-radioactive isotopes that can act as tracers used to model several chemical and biochemical systems. The chosen isotope can act as a label on that compound that can be identified through nuclear magnetic resonance (NMR) and mass spectrometry (MS). Some of the most common stable isotopes are 2H, 13C, 15N, and 18O, which can further be produced into NMR solvents, amino acids, nucleic acids, lipids, common metabolites and cell growth media. The compounds produced using stable isotopes are either specified by the percentage of labeled isotopes (that is, 30% uniformly labeled 13C glucose contains a mixture that is 30% labeled with 13C isotope and 70% naturally labeled carbon) or by the specifically labeled carbon positions on the compound (that is, 1-13C glucose which is labeled at the first carbon position of glucose). A network of reactions adopted from the glycolysis pathway and the pentose phosphate pathway is shown in which the labeled carbon isotope rearranges to different carbon positions throughout the network of reactions. The network starts with fructose 6-phosphate (F6P), which has six carbon atoms with a label 13C at carbon positions 1 and 2. 1,2-13C F6P becomes two glyceraldehyde 3-phosphate (G3P), one 2,3-13C T3P and one unlabeled T3P. The 2,3-13C T3P can now be reacted with sedoheptulose 7-phosphate (S7P) to form an unlabeled erythrose 4-phosphate(E4P) and a 5,6-13C F6P. The unlabeled T3P will react with the S7P to synthesize unlabeled products.
==== Land ==== The Peak Tram, Hong Kong's first public transport system, has provided funicular rail transport between Central and Victoria Peak since 1888. The Central and Western District has an extensive system of escalators and moving pavements, which, together with the Mid-Levels escalator system, is the world's longest outdoor covered escalator system. Hong Kong Tramways' tram network covers a portion of Hong Kong Island, covering from Kennedy Town to Shau Kei Wan, with a branch to Happy Valley. It operates 6 routes and has had a ridership of 42,558 in 2022. It began servicing Hong Kong since 1904. Hong Kong Tramways currently holds the Guinness World Record as the "Largest double-decker tram fleet in service", certified on 30 July 2021, with a fleet of 165 double-decker trams. The fleet of trams was mostly built by Hong Kong Tramways.
Chavibetol is an organic chemical compound of the phenylpropanoid class. It is one of the primary constituents of the essential oil from the leaves of the betel plant (Piper betel) and catatia. It is an aromatic compound with a spicy odor.
== Genetics == LNS is due to mutations in the HPRT1 gene, so named because it codes for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT or HGPRT, EC 2.4.2.8). This enzyme is involved in the biochemical pathways the body uses to produce purines, one of the components of DNA and RNA. Defects of this enzyme lead to increased production of uric acid. Since the HPRT gene is located on the X chromosome, LNS is an X-linked inherited disease. The father of an affected male will not be the carrier of the mutant allele, and will not have the disease. An obligate carrier would be a woman who has an affected son and one other affected relative in the maternal line. If a woman is the first in her family with an affected son, Haldane's rule predicts a 2/3 chance that she is a carrier and a 1/3 chance that the son has a new germline mutation. The risk to siblings of an affected individual depends upon the carrier status of the mother herself. A 50% chance is given to any female who is a carrier to transmit the HPRT1 mutation in each pregnancy. Sons who inherit the mutation will be affected while daughters who inherit the mutation are carriers. Therefore, with each pregnancy, a carrier female has a 25% chance of having a male that is affected, a 25% chance of having a female that is a carrier, and a 50% chance of having a normal male or female. Males with LNS generally do not reproduce due to the characteristics of the disease. However, if a male with a less severe phenotype reproduces, all of his daughters are carriers, and none of his sons will be affected.
== Early life, education, and career == Wittman was born in Washington, D.C., the son of adoptive parents Regina C. (née Wood) and Frank Joseph Wittman. His father was of German descent and his mother's ancestors included immigrants from Ireland and Canada. He grew up in Henrico County, Virginia. He attended the Virginia Polytechnic Institute and State University (Virginia Tech) as a member of the Corps of Cadets and Army ROTC and studied biology. While at Virginia Tech, he spent the summers working at a tomato cannery and on a fishing vessel. Also while in college, Wittman was a member of the Delta Tau Delta fraternity. He earned a master's degree in public health from the University of North Carolina at Chapel Hill in 1990 and a Ph.D. from Virginia Commonwealth University in 2002. Wittman worked for 20 years with the Virginia Department of Health. He served as an environmental health specialist and was field director for the Division of Shellfish Sanitation. Wittman served on the Montross Town Council from 1986 to 1996 and as mayor of the Town of Montross from 1992 to 1996. Two of his major initiatives in this office were the overhaul of the sewage system and the development of a computerized system for tax billing. From 1996 to 2005, Wittman served on the Westmoreland County Board of Supervisors, the last two years as chair. He helped create new libraries and pushed for raises in teacher salaries.
Sources: en.wikipedia.org
=== Nonredox === Chorismate synthase (CS) catalyzes the last step in the shikimate pathway—the formation of chorismate. Two classes of CS are known, both of which require FMN, but are divided on their need for NADPH as a reducing agent. The proposed mechanism for CS involves radical species. The radical flavin species has not been detected spectroscopically without using a substrate analogue, which suggests that it is short-lived. However, when using a fluorinated substrate, a neutral flavin semiquinone was detected.
Some evidence suggests that amphetamine may be more strongly modulated by ovarian sex hormones than other psychostimulants such as methylphenidate, which may result in relatively greater variability in drug response across the menstrual cycle. Although preliminary observational evidence suggests potential benefit from adjusting amphetamine doses according to menstrual cycle phases, randomized controlled trials have not evaluated this practice.
=== Monitoring of human exposure === Pentachlorophenol may be measured in plasma or urine as an index of excessive exposure. This is usually performed by gas chromatography with electron-capture or mass-spectrometric detection. Since urine contains predominantly conjugated PCP in chronic exposure situations, prior hydrolysis of specimens is recommended. The current ACGIH biological exposure limits for occupational exposure to PCP are 5 mg/L in an end-of-shift plasma specimen and 2 mg/g creatinine in an end-of-shift urine specimen.
=== Phase 2 === 7-Oxoprasterone (7-keto-DHEA; HBL-9001; HL-9001; At-Ease) – undefined mechanism of action (immunomodulator) [4] [5] Amdiglurax (ALTO-100; NSI-189) – unknown mechanism of action (hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator) [6] [7] BI-1358894 – transient receptor potential cation channel TRPC4 and TRPC5 inhibitor [8] Cannabidiol (A-1002-N5S; CBD; Nantheia™) – cannabinoid, various actions [9] CORT-108297 (ADS-108297) – glucocorticoid receptor antagonist [10] Dronabinol (BX-1) – cannabinoid CB1 and CB2 receptor agonist [11] Iloperidone (Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril) – atypical antipsychotic (non-selective monoamine receptor modulator) [12] Ketamine intranasal (Ereska; PMI-100; PMI-150; SLS-002; TUR-002) – NMDA receptor antagonist and dissociative hallucinogen [13] Lithium cocrystal (AL-001; LiProSal; lithium salicylate/L-proline cocrystal) – undefined mechanism of action and mood stabilizer (improved formulation of lithium) [14] Methylone (MDMC; TSND-201) – serotonin–norepinephrine–dopamine releasing agent and entactogen Midomafetamine/citalopram (MDMA/citalopram) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen followed by a selective serotonin reuptake inhibitor Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [15] Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [16] Soclenicant (BNC-210; IW-2143) – α7-nicotinic acetylcholine receptor antagonist [17] SRX-246 (API-246) – vasopressin V1A receptor antagonist [18] Xenon (NBTX-001) – NMDA receptor antagonist [19]
== Applications == Due to its contribution to fibrinolysis, tissue plasminogen activator is used medically to treat blood clot-related disorders including thrombotic or embolic stroke, myocardial infarction, and pulmonary embolism. It is manufactured using recombinant techniques and is sold as alteplase, reteplase, and tenecteplase. Alteplase was the first of these versions to go on the market, and has the same structure as tPA. Reteplase and tenecteplase both received FDA approval after alteplase, and have nonidentical structures to tPA. These recombinant forms of tPA have been shown to have a longer half-life in the blood and greater resistance to inhibition, resulting in an increased capacity to treat thrombolytic diseases. Urokinase is similarly used in the medical field, specifically for the treatment of pulmonary embolism.
Sources: en.wikipedia.org
When allowed to react with superacids, sulfuric acid can act as a base and can be protonated, forming the [H3SO4]+ ion. Salts of [H3SO4]+ have been prepared (e.g. trihydroxyoxosulfonium hexafluoroantimonate(V) [H3SO4]+[SbF6]−) using the following reaction in liquid HF:
== Etymology == The singular alga is the Latin word for "seaweed" and retains that meaning in English. The etymology is obscure. Although some speculate that it is related to Latin algēre, "be cold", no reason is known to associate seaweed with temperature. A more likely source is alliga, "binding, entwining". The Ancient Greek word for "seaweed" was φῦκος (phŷkos), which could mean either the seaweed (probably red algae) or a red dye derived from it. The Latinization, fūcus, meant primarily the cosmetic rouge. The etymology is uncertain, but a strong candidate has long been some word related to the Biblical פוך (pūk), "paint" (if not that word itself), a cosmetic eye-shadow used by the Ancient Egyptians and other inhabitants of the eastern Mediterranean. It could be any color: black, red, green, or blue. The study of algae is most commonly called phycology (from Greek phykos 'seaweed'); the term algology is falling out of use.
== Oil == Peppermint oil has a high concentration of natural pesticides, mainly pulegone found mostly in "M. arvensis var. piperascens" (Mentha canadensis), and to a lesser extent in Mentha × piperita and menthone. It is known to repel some pest insects, including mosquitos. Main constituents of the essential oil from Mentha × piperita are menthol (41%) and menthone (23%). The oil is used in flavours and fragrances. Its aroma defines "peppermint".
== Products == Novo produces the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.